Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study evaluating nadunolimab in triple-negative breast cancer (TNBC). The ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

The productivity argument around AI is as valid as it used to be. However, a year later, we are seeing layoffs blamed on AI ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...

Odronextamab combined with CHOP showed high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile was manageable, with no new safety signals, and most patients ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF ...

Exogenous attention is a rapid, involuntary mechanism that automatically reallocates processing resources toward salient stimuli. It enhances visual sensitivity in the vicinity of the salient stimulus ...

GLP-1 receptor agonists (GLP-1 RAs) are transforming metabolic disease treatment, with analytical chemists playing a critical role in formulation, stability testing, and clinical trial support for ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

Researchers developed a blood test that spots ALS with 90% accuracy. The 46-gene panel could cut diagnostic delays that now ...